<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01682928</url>
  </required_header>
  <id_info>
    <org_study_id>STRONG-2012</org_study_id>
    <nct_id>NCT01682928</nct_id>
  </id_info>
  <brief_title>Hydrotherapy for the Reversal of Oligohydramnios</brief_title>
  <acronym>STRONG</acronym>
  <official_title>Submersion Therapy for the Reversal of Oligohydramnios; A Non-invasive Gentle Approach</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mednax Center for Research, Education, Quality and Safety</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Banner Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mednax Center for Research, Education, Quality and Safety</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      OBJECTIVE: To assess the efficacy of subtotal immersion therapy as an option to improve&#xD;
      maternal intravascular volume thereby improving both maternal and fetal hemodynamic status&#xD;
      with reversal of oligohydramnios. This will be measured utilizing the Amniotic Fluid Volume&#xD;
      (AFV) as the primary outcome. Secondary outcomes will be measured using Fetal Doppler&#xD;
      Studies, Maternal vital signs (Blood Pressure, Pulse Pressure, Weight, Pulse) and&#xD;
      input/output.&#xD;
&#xD;
      HYPOTHESIS: Oligohydramnios, secondary to depleted maternal intravascular volume, can be&#xD;
      reversed by improving feto- and uteroplacental perfusion with subtotal immersion therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND: The volume of amniotic fluid is relevant clinically as derangements that decrease&#xD;
      volume result in a condition known as oligohydramnios, which can have profound implications&#xD;
      on perinatal outcome. The incidence of oligohydramnios is 2.3%1,2,3 and measurements of&#xD;
      amniotic fluid volume (AFV) has become a standard in fetal surveillance in the evaluation of&#xD;
      high risk pregnancies as oligohydramnios is associated with intrauterine growth restriction,&#xD;
      respiratory distress syndrome, post-maturity syndrome, and chronic fetal hypoxia.&#xD;
      Oligohydramnios may also play a role in fetal malpresentation, umbilical cord compression,&#xD;
      meconium staining, and increased operative delivery.3,4, 5,6 Oligohydramnios is commonly&#xD;
      defined as an AFV of 5 cm or less. An AFV of 8 cm represents the fifth percentile of normal&#xD;
      AFV values.7 It has been observed that delivery in the setting of isolated oligohydramnios,&#xD;
      irrespective of an otherwise uncomplicated term gestation free of maternal disease, has&#xD;
      become routine thereby increasing maternal morbidity particularly in context of operative&#xD;
      delivery or failed inductions. 3&#xD;
&#xD;
      In order to understand oligohydramnios it is first important to understand intrauterine water&#xD;
      and progressive changes that occur with normal human gestation. At term, it is reported that&#xD;
      total water accumulation is approximately 3.5L, with 2400 mL in the fetus, 400 mL in the&#xD;
      placenta, and 700 mL in the amniotic fluid.8 In 1989, Brace and colleagues determined&#xD;
      amniotic fluid volume (AFV) as a function of gestational age. They reported an increase in&#xD;
      mean values from 30mL at 10weeks to 190mL at 16wks to 780mL at 32-35wks after which time AFV&#xD;
      decreases, especially in post-term pregnancies. It is important to realize; however, that the&#xD;
      pattern of volume fluctuation as a function of gestational age may vary considerably between&#xD;
      individuals. As a general rule AFV increases at a rate of 10ml/wk at the beginning of the&#xD;
      fetal period, this rate of expansion increases to 50-60ml/wk from 19 to 25wks at which time a&#xD;
      gradual decrease begins to take place until the rate of exchange is zero around 34wks.&#xD;
&#xD;
      The pathophysiology of amniotic fluid regulation is not entirely understood at this current&#xD;
      date, but it is safe to state that AFV is the integrated sums of the inflow and outflow&#xD;
      tracts of the amniotic space.8 Because fluid can move with relative ease between fetal and&#xD;
      maternal blood across the placenta and amniotic membranes it stands to reason that a maternal&#xD;
      hypovolemia secondary to dehydration would lead to the development of oligohydramnios. This&#xD;
      was indeed shown to be the case by Sherer, et al in their 1990 publication. Furthermore, both&#xD;
      oral and serum hydration as a way to increase maternal volume have been shown to be effective&#xD;
      treatments for oligohydramnios.3,11-16&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor enrollment&#xD;
  </why_stopped>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1. Primary: Number of Participants With Reversal of Oligohydramnios Using AFV Measures</measure>
    <time_frame>days 3, and 7 or discharge</time_frame>
    <description>Subjects amniotic fluid index via ultrasound on days 3, 5 and 7 of study participation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metabolic Status</measure>
    <time_frame>admission, days 3, 5, 7/discharge and delivery</time_frame>
    <description>Secondary:&#xD;
- Changes in maternal hemodynamic status by mobilizing extravascular fluid</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Oligohydramnios</condition>
  <arm_group>
    <arm_group_label>IV/Oral Hydration and Bedrest</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Maternal BP (sitting)&#xD;
Pulse Pressure&#xD;
Pulse&#xD;
Urine Specific Gravity BID&#xD;
Fetal Heart Rate&#xD;
Maternal Body Weight US Procedures&#xD;
AC/EFW&#xD;
Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})&#xD;
Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})&#xD;
AFI (Baseline, day 3, 7 {or Discharge})&#xD;
ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:&#xD;
1 Liter Water PO over 2 hours&#xD;
1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\hr for duration of the study participation&#xD;
Strict I/O's&#xD;
Vital signs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydrotherapy Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Maternal BP (sitting)&#xD;
Pulse Pressure&#xD;
Pulse&#xD;
Urine Specific Gravity BID&#xD;
Fetal Heart Rate&#xD;
Maternal Body Weight US Procedures&#xD;
AC/EFW&#xD;
Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})&#xD;
o 1 hour +/- 30 minutes after submersion therapy&#xD;
Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})&#xD;
o 1 hour +/- 30 minutes after submersion therapy&#xD;
AFI (Baseline, day 3, 7 {or Discharge}) o 1 hour +/- 30 minutes after submersion therapy&#xD;
ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:&#xD;
1 Liter Water PO over 2 hours&#xD;
1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\hr for duration of the study participation&#xD;
Strict I/O's&#xD;
Vital signs&#xD;
HYDROTHERAPY TWICE DAILY FOR 3-7 DAYS o Blood pressure, pulse, pulse pressure, body weight, and fetal heart rate before and after submersion therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV/Oral Hydration and Bedrest</intervention_name>
    <description>Maternal BP (sitting)&#xD;
Pulse Pressure&#xD;
Pulse&#xD;
Urine Specific Gravity BID&#xD;
Fetal Heart Rate&#xD;
Maternal Body Weight US Procedures&#xD;
AC/EFW&#xD;
Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})&#xD;
Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})&#xD;
AFI (Baseline, day 3, 7 {or Discharge})&#xD;
ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:&#xD;
1 Liter Water PO over 2 hours&#xD;
1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\hr for duration of the study participation&#xD;
Strict I/O's&#xD;
Vital signs</description>
    <arm_group_label>IV/Oral Hydration and Bedrest</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hydrotherapy</intervention_name>
    <description>Maternal BP (sitting)&#xD;
Pulse Pressure&#xD;
Pulse&#xD;
Urine Specific Gravity BID&#xD;
Fetal Heart Rate&#xD;
Maternal Body Weight US Procedures&#xD;
AC/EFW&#xD;
Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})&#xD;
o 1 hour +/- 30 minutes after submersion therapy&#xD;
Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})&#xD;
o 1 hour +/- 30 minutes after submersion therapy&#xD;
AFI (Baseline, day 3, 7 {or Discharge}) o 1 hour +/- 30 minutes after submersion therapy&#xD;
ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:&#xD;
1 Liter Water PO over 2 hours&#xD;
1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\hr for duration of the study participation&#xD;
Strict I/O's&#xD;
Vital signs&#xD;
HYDROTHERAPY TWICE DAILY FOR 3-7 DAYS o Blood pressure, pulse, pulse pressure, body weight, and fetal heart rate before and after submersion therapy</description>
    <arm_group_label>Hydrotherapy Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Maternal Age &gt;18 years&#xD;
&#xD;
          -  Oligohydramnios: diagnosed by sonography (defined AFV&lt;8cm)&#xD;
&#xD;
          -  Singleton Pregnancy&#xD;
&#xD;
          -  Intact membranes&#xD;
&#xD;
          -  Gestational age 24 - 36 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Indication for urgent delivery (severe PET, HELLP syndrome, persistent fetal hypoxemia&#xD;
             [non-reassuring fetal heart rate pattern])&#xD;
&#xD;
          -  Ruptured amniotic membranes; PPROM, PROM, SROM&#xD;
&#xD;
          -  Fever (&gt;38C)&#xD;
&#xD;
          -  Multiple gestation&#xD;
&#xD;
          -  &gt;37 week gestation&#xD;
&#xD;
          -  Lethal Fetal anomalies and/or demise&#xD;
&#xD;
          -  Maternal Cardiovascular disease&#xD;
&#xD;
          -  Maternal Renal disease&#xD;
&#xD;
          -  Maternal Pulmonary disease (other than asthma)&#xD;
&#xD;
          -  Patients using prostaglandin inhibitors, NSAIDs3,15 (within 1 week of enrollment,&#xD;
             other than baby asprin)&#xD;
&#xD;
          -  Non-English speaking&#xD;
&#xD;
          -  Vaginal Infections and/or active skin lesions&#xD;
&#xD;
          -  Placenta Previa and/or Unexplained Vaginal Bleeding&#xD;
&#xD;
          -  BMI &gt; 45&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas H Strong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Obstetrix Medical Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Banner Good Samaritan Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 6, 2012</study_first_submitted>
  <study_first_submitted_qc>September 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2012</study_first_posted>
  <results_first_submitted>August 28, 2019</results_first_submitted>
  <results_first_submitted_qc>March 27, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 30, 2020</results_first_posted>
  <last_update_submitted>March 27, 2020</last_update_submitted>
  <last_update_submitted_qc>March 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oligohydramnios</keyword>
  <keyword>Hydrotherapy</keyword>
  <keyword>Pregnancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oligohydramnios</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment began April 8, 2012 and ended April 2014. Recruitment took place at Banner Good Samaritan hospital based on Banner IRB approval.</recruitment_details>
      <pre_assignment_details>There were no pre-assignment events.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>IV/Oral Hydration and Bedrest</title>
          <description>1 Liter Water PO over 2 hours&#xD;
1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\hr for duration of the study participation Strict I/O's Vital signs US Procedures&#xD;
AC/EFW&#xD;
Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})&#xD;
Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})&#xD;
AFI (Baseline, day 3, 7 {or Discharge})</description>
        </group>
        <group group_id="P2">
          <title>Hydrotherapy Group</title>
          <description>US Procedures&#xD;
AC/EFW&#xD;
Umbilical Artery Doppler Flow (Baseline,&#xD;
Uterine Artery Doppler Flow (Baseline,&#xD;
AFI (Baseline,&#xD;
Strict I/O's&#xD;
Vital signs&#xD;
HYDROTHERAPY TWICE DAILY FOR 3-7 DAYS&#xD;
o Blood pressure, pulse, pulse pressure, body weight, and fetal heart rate before and after submersion therapy Hydrotherapy: • Maternal BP (sitting)&#xD;
Pulse Pressure&#xD;
Pulse&#xD;
Urine Specific Gravity BID&#xD;
Fetal Heart Rate&#xD;
Maternal Body Weight US Procedures&#xD;
AC/EFW&#xD;
Umbilical Artery Doppler Flow&#xD;
Uterine Artery Doppler Flow • AFI (Baseline, day 3, 7 {or Discharge})</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2">2 subjects in this Arm</participants>
                <participants group_id="P2" count="2">2 subjects in this Arm</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>IV/Oral Hydration and Bedrest</title>
          <description>IV/Oral Hydration and Bedrest:&#xD;
Maternal BP (sitting)&#xD;
Pulse Pressure&#xD;
Pulse&#xD;
Urine Specific Gravity BID&#xD;
Fetal Heart Rate&#xD;
Maternal Body Weight US Procedures&#xD;
AC/EFW&#xD;
Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})&#xD;
Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})&#xD;
AFI (Baseline, day 3, 7 {or Discharge})&#xD;
ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:&#xD;
1 Liter Water PO over 2 hours&#xD;
1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\hr for duration of the study participation&#xD;
Strict I/O's&#xD;
Vital signs</description>
        </group>
        <group group_id="B2">
          <title>Hydrotherapy Group</title>
          <description>• HYDROTHERAPY TWICE DAILY FOR 3-7 DAYS&#xD;
o Blood pressure, pulse, pulse pressure, body weight, and fetal heart rate before and after submersion therapy&#xD;
Hydrotherapy:&#xD;
Maternal BP (sitting)&#xD;
Pulse Pressure&#xD;
Pulse&#xD;
Urine Specific Gravity BID&#xD;
Fetal Heart Rate&#xD;
Maternal Body Weight US Procedures&#xD;
AC/EFW&#xD;
Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})&#xD;
o 1 hour +/- 30 minutes after submersion therapy&#xD;
AFI (Baseline, day 3, 7 {or Discharge}) o 1 hour +/- 30 minutes after submersion therapy&#xD;
ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:&#xD;
1 Liter Water PO over 2 hours&#xD;
1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\hr for duration of the study participation&#xD;
Strict I/O's&#xD;
Vital signs</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.5" lower_limit="29" upper_limit="34"/>
                    <measurement group_id="B2" value="23" lower_limit="21" upper_limit="25"/>
                    <measurement group_id="B3" value="27.25" lower_limit="21" upper_limit="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>1. Primary: Number of Participants With Reversal of Oligohydramnios Using AFV Measures</title>
        <description>Subjects amniotic fluid index via ultrasound on days 3, 5 and 7 of study participation.</description>
        <time_frame>days 3, and 7 or discharge</time_frame>
        <population>no formal analysis done on the 4 enrolled patients, study halted due to poor enrollment. Data cannot be reported due to participant privacy.</population>
        <group_list>
          <group group_id="O1">
            <title>IV/Oral Hydration and Bedrest</title>
            <description>IV/Oral Hydration and Bedrest for up to 7 days&#xD;
US Procedures&#xD;
AC/EFW&#xD;
Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})&#xD;
Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})&#xD;
AFI (Baseline, day 3, 7 {or Discharge})&#xD;
ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:&#xD;
1 Liter Water PO over 2 hours&#xD;
1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\hr for duration of the study participation&#xD;
Strict I/O's&#xD;
Vital signs&#xD;
: • Maternal BP (sitting)&#xD;
Pulse Pressure&#xD;
Pulse&#xD;
Urine Specific Gravity BID&#xD;
Fetal Heart Rate&#xD;
Maternal Body Weight US Procedures&#xD;
AC/EFW&#xD;
Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})&#xD;
Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})&#xD;
AFI (Baseline, day 3, 7 {or Discharge})&#xD;
ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:&#xD;
1 Liter Water PO over 2 hours&#xD;
1 Liter IV</description>
          </group>
          <group group_id="O2">
            <title>Hydrotherapy Group</title>
            <description>HYDROTHERAPY TWICE DAILY FOR 3-7 DAYS&#xD;
Maternal BP (sitting) US Procedures&#xD;
AC/EFW&#xD;
Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})&#xD;
o 1 hour +/- 30 minutes after submersion therapy&#xD;
Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})&#xD;
o 1 hour +/- 30 minutes after submersion therapy&#xD;
AFI (Baseline, day 3, 7 {or Discharge}) o 1 hour +/- 30 minutes after submersion therapy&#xD;
ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:&#xD;
1 Liter Water PO over 2 hours&#xD;
1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\hr for duration of the study participation&#xD;
Strict I/O's&#xD;
Vital signs&#xD;
Blood pressure, pulse, pulse pressure, body weight, and fetal heart rate before and after submersion therapy&#xD;
Hydrotherapy: • Maternal BP (sitting)&#xD;
Pulse Pressure&#xD;
Pulse&#xD;
Urine Specific Gravity BID&#xD;
Fetal Heart Rate&#xD;
Maternal Body Weight</description>
          </group>
        </group_list>
        <measure>
          <title>1. Primary: Number of Participants With Reversal of Oligohydramnios Using AFV Measures</title>
          <description>Subjects amniotic fluid index via ultrasound on days 3, 5 and 7 of study participation.</description>
          <population>no formal analysis done on the 4 enrolled patients, study halted due to poor enrollment. Data cannot be reported due to participant privacy.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Metabolic Status</title>
        <description>Secondary:&#xD;
- Changes in maternal hemodynamic status by mobilizing extravascular fluid</description>
        <time_frame>admission, days 3, 5, 7/discharge and delivery</time_frame>
        <population>No analysis done as study halted for poor enrollment only 4 subjects enrolled total. Detailed Data cannot be reported due to participant privacy.</population>
        <group_list>
          <group group_id="O1">
            <title>IV/Oral Hydration and Bedrest</title>
            <description>IV/Oral Hydration and Bedrest up to 7 days&#xD;
AC/EFW&#xD;
Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})&#xD;
Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})&#xD;
AFI (Baseline, day 3, 7 {or Discharge})&#xD;
ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:&#xD;
1 Liter Water PO over 2 hours&#xD;
1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\hr for duration of the study participation&#xD;
Strict I/O's&#xD;
Vital signs&#xD;
: • Maternal BP (sitting)&#xD;
Pulse Pressure&#xD;
Pulse&#xD;
Urine Specific Gravity BID&#xD;
Fetal Heart Rate&#xD;
Maternal Body Weight US Procedures&#xD;
AC/EFW&#xD;
Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})&#xD;
Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})&#xD;
AFI (Baseline, day 3, 7 {or Discharge})&#xD;
ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:&#xD;
1 Liter Water PO over 2 hours&#xD;
1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\hr for duration of the study participation&#xD;
Strict I/O's&#xD;
Vital sign</description>
          </group>
          <group group_id="O2">
            <title>Hydrotherapy Group</title>
            <description>• HYDROTHERAPY TWICE DAILY FOR 3-7 DAYS&#xD;
ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:&#xD;
1 Liter Water PO over 2 hours&#xD;
1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\hr for duration of the study participation&#xD;
Strict I/O's&#xD;
Vital signs&#xD;
Blood pressure, pulse, pulse pressure, body weight, and fetal heart rate before and after submersion therapy&#xD;
Hydrotherapy: • Maternal BP (sitting)&#xD;
Pulse Pressure&#xD;
Pulse&#xD;
Urine Specific Gravity BID&#xD;
Fetal Heart Rate&#xD;
Maternal Body Weight US Procedures&#xD;
AC/EFW&#xD;
Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge}) o 1 hour +/- 30 minutes after submer</description>
          </group>
        </group_list>
        <measure>
          <title>Metabolic Status</title>
          <description>Secondary:&#xD;
- Changes in maternal hemodynamic status by mobilizing extravascular fluid</description>
          <population>No analysis done as study halted for poor enrollment only 4 subjects enrolled total. Detailed Data cannot be reported due to participant privacy.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years and 4 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>IV/Oral Hydration and Bedrest</title>
          <description>Maternal BP (sitting)&#xD;
Pulse Pressure&#xD;
Pulse&#xD;
Urine Specific Gravity BID&#xD;
Fetal Heart Rate&#xD;
Maternal Body Weight US Procedures&#xD;
AC/EFW&#xD;
Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})&#xD;
Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})&#xD;
AFI (Baseline, day 3, 7 {or Discharge})&#xD;
ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:&#xD;
1 Liter Water PO over 2 hours&#xD;
1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\hr for duration of the study participation&#xD;
Strict I/O's&#xD;
Vital signs&#xD;
IV/Oral Hydration and Bedrest: • Maternal BP (sitting)&#xD;
Pulse Pressure&#xD;
Pulse&#xD;
Urine Specific Gravity BID&#xD;
Fetal Heart Rate&#xD;
Maternal Body Weight US Procedures&#xD;
AC/EFW&#xD;
Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})&#xD;
Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})&#xD;
AFI (Baseline, day 3, 7 {or Discharge})</description>
        </group>
        <group group_id="E2">
          <title>Hydrotherapy Group</title>
          <description>Maternal BP (sitting)&#xD;
Pulse Pressure&#xD;
Pulse&#xD;
Urine Specific Gravity BID&#xD;
Fetal Heart Rate&#xD;
Maternal Body Weight US Procedures&#xD;
AC/EFW&#xD;
Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})&#xD;
o 1 hour +/- 30 minutes after submersion therapy&#xD;
Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})&#xD;
o 1 hour +/- 30 minutes after submersion therapy&#xD;
AFI (Baseline, day 3, 7 {or Discharge}) o 1 hour +/- 30 minutes after submersion therapy&#xD;
ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:&#xD;
1 Liter Water PO over 2 hours&#xD;
1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\hr for duration of the study participation&#xD;
Strict I/O's&#xD;
Vital signs&#xD;
HYDROTHERAPY TWICE DAILY FOR 3-7 DAYS o Blood pressure, pulse, pulse pressure, body weight, and fetal heart rate before and after submersion therapy</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ana Braescu</name_or_title>
      <organization>Mednax</organization>
      <phone>480-969-5999</phone>
      <email>ana_braescu@mednax.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

